Todd C. Davis is the Chief Executive Officer at Ligand Pharmaceuticals Incorporated, a position he has held since joining the company in 2019. With a robust background in the biopharmaceutical industry, Davis brings a wealth of experience and leadership to Ligand. Prior to his role at Ligand, he served as the President and Chief Operating Officer at Albany Molecular Research Inc. (AMRI), where he was instrumental in driving the company's strategic growth and operational excellence. Davis's career also includes significant tenures at other notable companies such as Teva Pharmaceuticals and Bristol-Myers Squibb, where he honed his skills in various aspects of the pharmaceutical business, including sales, marketing, and operations. At Ligand Pharmaceuticals, Todd C. Davis has been pivotal in steering the company towards its goal of becoming a leader in developing and acquiring innovative technologies that help pharmaceutical companies discover and develop medicines. Under his leadership, Ligand has expanded its portfolio and strengthened its partnerships, significantly enhancing its market position. Davis's strategic vision has been crucial in navigating the complex landscape of drug development and commercialization, ensuring that Ligand remains at the forefront of the industry. His commitment to fostering a culture of innovation and collaboration has been a key factor in the company's success and continued growth. In addition to his professional achievements, Todd C. Davis is recognized for his contributions to the broader biopharmaceutical community. He actively participates in industry conferences and forums, sharing insights and best practices that help advance the field. Davis holds a Bachelor of Science degree in Biology from the University of Richmond and an MBA from the University of Michigan's Ross School of Business. His educational background, combined with his extensive industry experience, makes him a respected leader in the pharmaceutical sector.